Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

Very interesting and revealing post Maumar. So

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jamtomorrow2 Member Profile
 
Followed By 0
Posts 171
Boards Moderated 0
Alias Born 12/04/13
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2019 7:11:11 PM
Halozyme To Participate In 2019 Cantor Global Healthcare Conference PR Newswire (US) - 9/23/2019 8:00:00 AM
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Usi... PR Newswire (US) - 9/13/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 11:21:22 AM
Halozyme To Participate In 2019 Wells Fargo Healthcare Conference PR Newswire (US) - 8/26/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:19:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 4:13:31 PM
Halozyme Reports Second Quarter 2019 Results PR Newswire (US) - 8/6/2019 4:01:00 PM
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference PR Newswire (US) - 7/25/2019 8:00:00 AM
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 7/23/2019 4:01:00 PM
J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma Dow Jones News - 7/19/2019 7:45:00 AM
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALE... PR Newswire (US) - 7/19/2019 7:00:00 AM
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Te... PR Newswire (US) - 7/17/2019 8:00:00 AM
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire (US) - 7/12/2019 11:59:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/3/2019 4:02:19 PM
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Techno... PR Newswire (US) - 6/25/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 8:20:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 1:41:16 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/7/2019 5:11:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:45:58 PM
Halozyme To Participate In Upcoming Investor Conferences PR Newswire (US) - 6/4/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 5:24:28 PM
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire (US) - 5/22/2019 1:05:00 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:11:52 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:08:35 PM
jamtomorrow2   Friday, 02/01/19 10:19:15 PM
Re: None
Post # of 5691 
Very interesting and revealing post Maumar. So all the theories about Roche not seeking FDA approval of SQ Herceptin because the patents were expiring later in the US than in the EU were incorrect. In reality Roche had been told by the FDA that they were unlikely to approve SQ Herceptin presumably because of titer concerns. I guess they have changed their tone because of the success of SQ Herceptin in the EU without seemingly any side effects.

I hope the FDA aren’t going to take a similar hard line on the new Enhanze SQ candidates or HALO is in big trouble.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist